About 1%, or 3.2 million Americans, have venous skin ulcers and they are more common in older, people particularly women. Venous ulcers usually affect the lower legs and one out of 50 people over the age of 80 in the US have these painful ulcers. The results from a previous US FDA-cleared Phase II clinical trial indicated that human FGF-1 enhanced the healing of venous ulcers. In that study, a two-fold acceleration of healing was demonstrated and the drug was well tolerated. Zhittya will now seek to build on these earlier results to develop FGF-1 for the treatment of those very painful, chronic wounds, which if not healed can lead to wound infection and tissue loss.